P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

• Manisha Bhutani,
• Alfred Garfall,
• Katarina Uttervall,
• Saad Z Usmani,
• Lionel Karlin,
• Lotfi Benboubker,
• Hareth Nahi,
• Jesús San Miguel,
• Danielle Trancucci,
• Keqin Qi,
• Tara Stephenson,
• Alfredo Perales-Puchalt,
• Katherine Chastain,
• Ajai Chari

Affiliations

Manisha Bhutani

1 Levine Cancer Institute/Atrium Health, Charlotte, United States

Alfred Garfall

2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States

Katarina Uttervall

3 Karolinska University Hospital, Stockholm, Sweden

Saad Z Usmani

4 Memorial Sloan Kettering Cancer Center, New York, United States

Lionel Karlin

5 Centre Hospitalier Lyon Sud, Pierre-Bénite, France

Lotfi Benboubker

6 Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours, France

Hareth Nahi

7 Karolinska University Hospital at Huddinge, Stockholm, Sweden

Jesús San Miguel

8 University of Navarra, Pamplona, Spain

Danielle Trancucci

9 Janssen Research & Development, Raritan, United States

Keqin Qi

10 Janssen Research & Development, Titusville, United States

Tara Stephenson

11 Janssen Research & Development, Spring House, United States

Alfredo Perales-Puchalt

11 Janssen Research & Development, Spring House, United States

Katherine Chastain

9 Janssen Research & Development, Raritan, United States

Ajai Chari

12 Mount Sinai School of Medicine, New York, United States